Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES:
I. Determine the response rate and 1-year event-free survival in patients with severe
autoimmune hematologic disease treated with high-dose cyclophosphamide.